Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus)

Experimental Neurology

Volumn 184, Issue 1, 2003, Pages 536-548

  Eslamboli, Andisheh ^a   Cummings, Rosalyn M ^a   Ridley, Rosalind M ^a   Baker, Harry F ^a   Muzyczka, Nicholas ^b   Burger, Corinna ^b   Mandel, Ronald J ^b   Kirik, Deniz ^c   Annett, Lucy E ^d  

^a UK   (United Kingdom)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c LUND UNIVERSITY   (Sweden)

^d UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

Adeno associated viral vector; Behaviour; Gene therapy; Glial cell line derived neurotrophic factor; Marmoset monkey; Neuroprotection; Parkinson's disease

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; OXIDOPAMINE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALLITHRIX JACCHUS; CELL LOSS; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; DISABILITY; DISEASE ASSOCIATION; DOPAMINERGIC NERVE CELL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; FEMALE; FUNCTIONAL ASSESSMENT; HEAD POSITION; INJECTION; INNERVATION; MALE; MARMOSET; MICROSCOPIC ANATOMY; NERVE LESION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; SUBSTANTIA NIGRA; VIRUS RECOMBINANT;

EID: 0345257314     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2003.08.007     Document Type: Article

References (43)

1. Airaksinen M.S., Saarma M. The GDNF family signalling, biological functions and therapeutic value. Nat. Rev. Neurosci. 3:2002;383-394.
2. Andsberg G., Kokaia Z., Klein R.L., Muzyczka N., Lindvall O., Mandel R.J. Neuropathological and behavioral consequences of adeno-associated viral vector-mediated continuous intrastriatal neurotrophin delivery in a focal ischemia model in rats. Neurobiol. Dis. 9:2002;187-204.
3. Annett L.E., Rogers D.C., Hernandez T.D., Dunnett S.B. Behavioural analysis of unilateral monoamine depletion in the marmoset. Brain. 115:1992;825-856.
4. Berns K.I., Linden R.M. The cryptic life style of adeno-associated virus. Bioessays. 17:1995;237-245.
5. Chauhan N.B., Siegel G.J., Lee J.M. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain. J. Chem. Neuroanat. 21:2001;277-288.
6. Conway J.E., Zolotukhin S., Muzyczka N., Hayward G.S., Byrne B.J. Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap. J. Virol. 71:1997;8780-8789.
7. Costa S., Iravani M.M., Pearce R.K., Jenner P. Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets. Eur. J. Pharmacol. 412:2001;45-50.
8. Del-Fiacco M., Quartu M., Serra M.P., Follesa P., Lai M.L., Bachis A. Topographical localization of glial cell line-derived neurotrophic factor in the human brain stem an immunohistochemical study of prenatal, neonatal and adult brains. J. Chem. Neuroanat. 23:2002;29-48.
9. Eberling J.L., Bankiewicz K.S., Jordan S., VanBrocklin H.F., Jagust W.J. PET studies of functional compensation in a primate model of Parkinson's disease. Neuroreport. 8:1997;2727-2733.
10. Eslamboli, A., Baker, H.F., Ridley, R.M., Annett, L.E., 2003. Sensorimotor deficits in a unilateral intrastriatal 6-OHDA partial lesion model of Parkinson's disease in marmoset monkeys. Exp. Neurol. 183, 418-429.
11. Francois C., Percheron G., Yelnik J. Localization of nigrostriatal, nigrothalamic and nigrotectal neurons in ventricular coordinates in macaques. Neuroscience. 13:1984;61-76.
12. Freeman T.B. From transplants to gene therapy for Parkinson's disease. Exp. Neurol. 144:1997;47-50.
13. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J., Gerhardt G.A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature. 380:1996;252-255.
14. Georgievska B., Kirik D., Bjorklund A. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp. Neurol. 177:2002;461-474.
15. Georgievska B., Kirik D., Rosenblad C., Lundberg C., Bjorklund A. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport. 13:2002;75-82.
16. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9:2003;589-595.
17. Gundersen H.J.C., Jensen E.B. The efficiency of systematic sampling in stereology and its prediction. J. Microsc. 147:1987;229-263.
18. Hamilton J.F., Morrison P.F., Chen M.Y., Harvey-White J., Pernaute R.S., Phillips H., Oldfield E., Bankiewicz K.S. Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin. Exp. Neurol. 168:2001;155-161.
19. Kawamoto Y., Nakamura S., Matsuo A., Akiguchi I., Shibasaki H. Immunohistochemical localization of glial cell line-derived neurotrophic factor in the human central nervous system. Neuroscience. 100:2000;701-712.
20. Kearns C.M., Cass W.A., Smoot K., Kryscio R., Gash D.M. GDNF protection against 6-OHDA time dependence and requirement for protein synthesis. J. Neurosci. 17:1997;7111-7118.
21. Kearns C.M., Gash D.M. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res. 672:1995;104-111.
22. Kirik D., Georgievska B., Rosenblad C., Bjorklund A. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease. Eur. J. Neurosci. 13:2001;1589-1599.
23. Kirik D., Rosenblad C., Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152:1998;259-277.
24. Kirik D., Rosenblad C., Bjorklund A., Mandel R.J. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J. Neurosci. 20:2000;4686-4700.
25. Kirik D., Winkler C., Bjorklund A. Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration. J. Neurosci. 21:2001;2889-2896.
26. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitberg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z., Trono D., Hantraye P., Deglon N., Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science. 290:2000;767-773.
27. Lapchak P.A., Araujo D.M., Hilt D.C., Sheng J., Jiao S. Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease. Brain Res. 777:1997;153-160.
28. Lapchak P.A., Miller P.J., Collins F., Jiao S. Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats comparison of intraventricular and intranigral delivery. Neuroscience. 78:1997;61-72.
29. Lewis D.A., Sesack S.R. Dopamine systems in the primate brain. Bloom F.E., Bjorklund A., Hokfelt T. Handbook of Chemical Neuroanatomy, Vol. 13. The Primate Nervous System. Part 1. 1997;263-375 Elsevier Science Amsterdam B.V.
30. Mandel R.J., Snyder R.O., Leff S.E. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease. Exp. Neurol. 160:1999;205-214.
31. Mandel R.J., Spratt S.K., Snyder R.O., Leff S.E. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc. Natl. Acad. Sci. USA. 94:1997;14083-14088.
32. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr. Top. Microbiol. Immunol. 158:1992;97-129.
33. Nosrat C.A., Tomac A., Lindqvist E., Lindskog S., Humpel C., Stromberg I., Ebendal T., Hoffer B.J., Olson L. Cellular expression of GDNF mRNA suggests multiple functions inside and outside the nervous system. Cell Tissue Res. 286:1996;191-207.
34. Palfi S., Leventhal L., Chu Y., Ma S.Y., Emborg M., Bakay R., Deglon N., Hantraye P., Aebischer P., Kordower J.H. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J. Neurosci. 22:2002;4942-4954.
35. Samulski R.J., Sally M., Muzyczka N. Adeno-associated viral vectors. Friedman T. The Development of Human Gene Therapy. 1999;131-172 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
36. Stephan H., Baron G., Schwerdtfeger W.K. The Brain of the Common Marmoset (Callithrix jacchus), A Stereotaxic Atlas. 1980;Springer-Verlag, Berlin.
37. Sullivan A.M., Opacka-Juffry J., Blunt S.B. Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo. Eur. J. Neurosci. 10:1998;57-63.
38. Wang L., Muramatsu S., Lu Y., Ikeguchi K., Fujimoto K., Okada T., Mizukami H., Hanazono Y., Kume A., Urano F., Ichinose H., Nagatsu T., Nakano I., Ozawa K. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Ther. 9:2002;381-389.
39. West M.J., Slomianka L., Gundersen H.J. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat. Rec. 231:1991;482-497.
40. Winkler C., Kirik D., Bjorklund A., Cenci M.A. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 10:2002;165-186.
41. Xu L., Daly T., Gao C., Flotte T.R., Song S., Byrne B.J., Sands M.S., Parker-Ponder K. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Hum. Gene Ther. 12:2001;563-573.
42. Zolotukhin S., Byrne B.J., Mason E., Zolotukhin I., Potter M., Chesnut K., Summerford C., Samulski R.J., Muzyczka N. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6:1999;973-985.
43. Zurn A.D., Widmer H.R., Aebischer P. Sustained delivery of GDNF towards a treatment for Parkinson's disease. Brain Res. Brain Res. Rev. 36:2001;222-229.